Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated February 11, 2026, serves as a transaction notification for Persons Discharging Managerial Responsibilities (PDMRs). The report details the vesting of deferred investment awards under the GlaxoSmithKline Deferred Investment Award Programme for three senior executives on February 10, 2026.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to specific executive compensation transactions:
- Instrument: Ordinary shares of 31 1/2 pence each (ISIN: GB00BN7SWP63).
- Transaction Price: £21.68 per share.
- Total Notional Shares Involved: 62,448.738 shares across three executives.
- Total Cash Value (Pre-tax): £1,353,888.50.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely records the scheduled vesting of the final 25% of awards granted on February 10, 2021, resulting in cash payments to the named executives.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a statutory disclosure of insider transactions.
Investor Verification Checklist
- Verify the vesting schedule and terms of the GlaxoSmithKline Deferred Investment Award Programme.
- Confirm the share price of £21.68 against market data for February 10, 2026.
- Review the total compensation packages for CEO Luke Miels, President Regis Simard, and CEO Deborah Waterhouse to contextualize these payouts.
- Note that this filing does not reflect the company's broader financial performance for the period.